Regulatory and HTA bodies now require robust comparative evidence, yet for novel therapies like CAR-T, randomized controlled trials are often not feasible. Since ZUMA-5 was a single-arm trial, statistical models that emulate clinical trials and an external control arm were needed.
RainCity helped develop the SCHOLAR-5 external control arm and applied advanced propensity score methods to compare outcomes against the ZUMA-5 trial.
Published in Blood and central to multiple HTA submissions, SCHOLAR-5 has also supported additional research on treatment patterns and POD24 outcomes